Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Till Hansen

Endocrinology, Diabetes & Metabolism Wailuku, HI Medical Doctor

NPI 1720173214 CMS profile 213852

24 N Church St, Suite 403, Wailuku, HI 96793

Open in the dashboard

General payments

$488,148

810 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Till Hansen of Wailuku, HI is reported in the CMS Open Payments database as having received $488,148 across 810 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $82,607 123
2024 General $76,211 142
2023 General $50,547 83
2022 General $90,917 101
2021 General $71,136 134
2020 General $62,814 124
2019 General $53,916 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Till Hansen
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Till Hansen were reported at $82,607. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Till Hansen Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $53,916 $494 $123–$2,253 $163
2020 $62,814 $335 $85–$1,841 $114
2021 $71,136 $398 $88–$1,981 $132
2022 $90,917 $364 $88–$1,568 $149
2023 $50,547 $420 $113–$1,614 $160
2024 $76,211 $440 $121–$1,646 $164
2025 $82,607 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $214,237 334 payments
  2. Lilly USA, LLC $206,865 362 payments
  3. AstraZeneca Pharmaceuticals LP $47,670 73 payments
  4. Corcept Therapeutics $15,317 18 payments
  5. Janssen Pharmaceuticals, Inc $3,162 10 payments
  6. Amarin Pharma Inc. $259 4 payments
  7. NxStage Medical, Inc. $175 3 payments
  8. Radius Health, Inc. $145 2 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $141 2 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $100 1 payment
  11. Other $78 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $421,595 414 payments
  2. Travel and Lodging $46,742 205 payments
  3. Food and Beverage $11,741 175 payments
  4. Consulting Fee $7,731 3 payments
  5. Education $340 13 payments
Products named General payments · program years 2019–2025
  1. MOUNJARO $189,529 304 payments
  2. RYBELSUS $93,119 156 payments
  3. Ozempic $67,203 110 payments
  4. FARXIGA $47,481 70 payments
  5. Saxenda $17,064 29 payments
  6. Wegovy $16,753 24 payments
  7. Korlym $15,317 18 payments
  8. Tresiba $12,514 12 payments
  9. INVOKANA $3,162 10 payments
  10. TRULICITY $304 7 payments
  11. Other $1,066 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

810 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record